key: cord-0865502-vafxb5md authors: Kanduc, Darja title: Thromboses and Hemostasis Disorders Associated with COVID-19: The Possible Causal Role of Cross-Reactivity and Immunological Imprinting date: 2021-06-26 journal: Glob Med Genet DOI: 10.1055/s-0041-1731068 sha: 684731e7cc8391355c408a856c79f22a28f98c62 doc_id: 865502 cord_uid: vafxb5md By examining the issue of the thromboses and hemostasis disorders associated with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) through the lens of cross-reactivity, it was found that 60 pentapeptides are shared by SARS-CoV-2 spike glycoprotein (gp) and human proteins that— when altered, mutated, deficient or, however, improperly functioning— cause vascular diseases, thromboembolic complications, venous thrombosis, thrombocytopenia, coagulopathies, and bleeding, inter alia. The peptide commonality has a relevant immunological potential as almost all of the shared sequences are present in experimentally validated SARS-CoV-2 spike gp-derived epitopes, thus supporting the possibility of cross-reactions between the viral gp and the thromboses-related human proteins. Moreover, many of the shared peptide sequences are also present in pathogens to which individuals have previously been exposed following natural infection or vaccinal routes, and of which the immune system has stored imprint. Such an immunological memory might rapidly trigger anamnestic secondary cross-reactive responses of extreme affinity and avidity, in this way explaining the thromboembolic adverse events that can associate with SARS-CoV-2 infection or active immunization. sequences shared between the SARS-CoV-2 spike gp and human proteins related to thromboembolic events can possibly generate pathogenic autoantibodies via cross-reactivity and immunologic imprinting phenomena, in this way leading to thromboses and hemostasis disorders. Peptide sharing between spike gp (NCBI, GenBank Protein Accession, ID: QHD43416.1) from SARS-CoV-2 and human proteins related to thromboses and hemostasis disorders was analyzed as previously detailed. [4] [5] [6] In brief, pentapeptides were used as sequence probes since a peptide grouping formed by five amino acid (aa) residues defines a minimal immune determinant that can (1) induce highly specific antibodies, and (2) determine antigen-antibody specific interaction. 7, 8 Human proteins linked to thromboses and hemostasis disorders were retrieved from UniProtKB database (www.uniprot.org). 9 Methodologically the spike gp primary sequence was dissected into pentapeptides offset by one residue (i.e., MFVFL, FVFLV, VFLVL, FLVLL, and so forth) and the resulting viral pentapeptides were analyzed for occurrences within the human proteins related to thromboses and hemostasis disorders. Then, the shared peptides were also controlled for occurrences in the pathogens Bordetella pertussis, Corynebacterium diphtheriae, Clostridium tetani, Haemophilus influenzae, and Neisseria meningitidis. The immunological potential of the peptides shared between SARS-CoV-2 spike gp and thrombosis-related proteins was analyzed by searching the Immune Epitope DataBase (IEDB [www.iedb.org/]) 10 for immunoreactive SARS-CoV-2 spike gp-derived epitopes hosting the shared pentaptides. Peptide Sharing between SARS-CoV-2 Spike Glycoprotein and Thromboses-Related Human Proteins ►Table 1 shows that 60 minimal immune determinants are shared between SARS-CoV-2 spike gp and 44 human proteins that-when altered, mutated, deficient or, however, improperly functioning-may cause diseases that include The data shown in ►Table 1 are quantitatively impressive and become strikingly preeminent from a pathological perspective when analyzed for their immunological potential. Indeed, exploration of the IEDB 10 reveals that nearly all the shared pentapeptides described in ►Table 1 are also disseminated among SARS-CoV-2 spike gp-derived epitopes that have been experimentally validated as immunoreactive and are cataloged at the IEDB database (http://www.iedb.org). 10 That is, ►Table 2 concretely supports the possibility that autoimmune cross-reactions may be triggered by SARS-CoV-2 infection/active immunization and hit human proteins related to thrombotic/thromboembolic disorders and coagulopathies, inter alia. Clinically, the vastity of the potential immunological cross-reactivity that emerges from ►Table 2 indicates that mild-to-moderate and severe forms of thrombosis and coagulopathy may unavoidably accompany SARS-CoV-2 infection/active immunization. As already highlighted also in other infection models, [68] [69] [70] [71] one has to consider that immunologic memory can powerfully enhance and amplify the autoimmune crossreactivity potential because of interpathogen peptide sharing. Indeed, as a rule, the immune system recalls preexisting memory responses toward past infections rather than inducing ex novo responses toward the recent ones since hallmark of the immune system is the memory for the immune determinants it has previously encountered. 72, 73 Here, comparative sequence analyses show that 31 out of the 60 minimal immune determinants common to SARS-CoV-2 spike gp and human proteins related to thromboses are also widespread in pathogens, such as B. pertussis, C. diphtheriae, C. tetani, H. influenzae, and N. meningitidis, that are in pathogens with which, in general, an individual has already come into contact during his life due to infections or by vaccination (►Table 3). Hence, ►Table 3 indicates the possibility that a preexisting immune response to previously encountered pathogens (in the present case: B. pertussis, C. tetani, C. diphtheriae, H. influenzae, and/or N. meningitidis) might be magnified and intensified following SARS-CoV-2 infection/active immunization. That is, immunological imprinting can start a chain of events according to which followings can be measured: • Following exposure to SARS-CoV-2, the primary response to the virus can turn into a secondary response to previously encountered pathogens of which the immune system has stored an immunological memory. • The anamnestic secondary and, by definition, extremely powerful response against immune determinants previously encountered implies not only that a low or no immune response will be evoked against the pathogen lastly encountered, that is, SARS-CoV-2, but also entails that the anamnestic secondary reaction against the early sensitizing pathogens-in the case in point, B. pertussis, C. tetani, C. diphtheriae, and/or N. meningitidis-will fail because those early sensitizing pathogens are no more present in the organism. • As a final result, the anamnestic, high affinity, high avidity, and extremely powerful secondary immune response triggered by the lastly encountered pathogen (SARS-CoV-2) and addressed toward past infections may find an outlet by hitting available human targets, that is, in the case in object, the human proteins related to thromboses and hemostasis diseases (►Table 1). The last decades witnessed the emerging of infectious diseases and, consequently, intensive application of immunization procedures. Concomitantly, concerns about possible adverse events have increased. A recent crucial example is the immunization campaign with the dengue vaccine that highlighted the risk of enhanced disease after vaccination. 74 Today, the clinical context associated with SARS-CoV-2 infection/active immunization is no different. Actually, understanding whether undesired collateral events, such as the thrombotic manifestations and bleeding disorders discussed in this study, may causally associate with the viral infection/active immunization is a fundamental step for fighting the current pandemic. In this context, the present study: • Analyzed the hypothesis that infectious agents can induce cross-reactive autoantibodies capable of hitting and al-tering human proteins that regulate hemostasis and coagulation. • Showed that numerous peptides endowed with an immunologic potential are common to SARS-CoV-2 spike gp and human proteins, when mutated, altered, deficient or improperly functioning, are associated with thromboses and hemostasis diseases (►Tables 1 and 2). • Documented that the peptide commonality extends to pathogens that usually have been already encountered by an individual during his life (►Table 3). Scientifically, the data indicate that peptide sharingassociated cross-reactivity and, in conjunction, immunological imprint might help explain some of the thromboembolic events that rapidly, massively, and violently may arise following SARS-CoV-2 infection/active immunization. Clinically, the present data warrant testing of patients' sera for autoantibodies against the peptide targets described in ►Tables 1-2 and 3, and reiterate the suggestion advanced already in 2000 75 that immunotherapies should take advantage of the principle of peptide uniqueness, that is, of peptides present in the antigen of interest and absent in the human proteome. 71, [76] [77] [78] [79] [80] [81] Funding None. None declared. Thromboembolic events in patients with SARS-CoV-2 Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins Potential crossreactivity of human immune responses against HCMV glycoprotein B Zika virus and autoimmunity: From microcephaly to Guillain-Barré syndrome, and beyond Pentapeptides as minimal functional units in cell biology and immunology Homology, similarity, and identity in peptide epitope immunodefinition UniProt: a worldwide hub of protein knowledge The Immune Epitope Database (IEDB): 2018 update Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 deficiency) Structure and properties of calphobindin II, an anticoagulant protein from human placenta Hermansky-Pudlak syndrome: mutation update AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis Identification of mutations in SLC4A1, GP1BA and HFE in a family with venous thrombosis of unknown cause by next-generation sequencing Deficiency of UDP-galactose:Nacetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IId Functions of human complement inhibitor C4b-binding protein in relation to its structure C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies Cystathionine β-synthase deficiency: different changes in proteomes of thrombosis-resistant Cbs -/-mice and thrombosisprone CBS -/-humans Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation Identification and characterization of CD39/vascular ATP diphosphohydrolase Ectonucleotidase modulation of lymphocyte function in gut and liver A mutation of the human EPHB2 gene leads to a major platelet functional defect Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family The association between thrombophilic gene mutations and recurrent pregnancy loss Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C Molecular analysis of factor VIII and factor IX genes in hemophilia patients: identification of novel mutations and molecular dynamics studies Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency Hereditary renal amyloidosis associated with a mutant fibrinogen alphachain Molecular basis for fibrinogen Dusart (A alpha 554 Arg->Cys) and its association with abnormal fibrin polymerization and thrombophilia Characterization of the murine coagulation factor X promoter Regulation of human coagulation factor X gene expression by GATA-4 and the Sp family of transcription factors The Author(s) GATA4 loss-of-function mutation underlies familial dilated cardiomyopathy Bernard soulier syndrome Genome-wide association analysis of young-onset stroke identifies a locus on chromosome 10q25 near HABP2 Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics Hermansky-Pudlak syndrome subtype 5 (HPS-5) novel mutation in a 65 year-old with oculocutaneous hypopigmentation and mild bleeding diathesis: the importance of recognizing a subtle phenotype Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1 Platelet glycoprotein gene Ia C807T, HPA-3, and Ibα VNTR polymorphisms are associated with increased ischemic stroke risk: Evidence from a comprehensive meta-analysis ST-elevation myocardial infarction, pulmonary embolism, and cerebral ischemic stroke in a patient with critically low levels of natural anticoagulants Hematologically important mutations: Glanzmann thrombasthenia Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention Kulozik AETHROMKID-Plus Studiengruppe der Gesellschaft für Thrombose-und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, PROC and PROS gene mutations Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S Protein Z levels and central retinal vein or artery occlusion The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis Thrombomodulin gene variations and thromboembolic disease Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial A randomized, doubleblind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation Association between single nucleotide polymorphisms in thrombospondins genes and coronary artery disease: A meta-analysis A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion Acquired von Willebrand syndrome associated with cardiovascular diseases Acquired von Willebrand syndrome The Guillain-Barrè peptide signatures: from Zika virus to campylobacter, and beyond Minimal immune determinants connect Zika virus, human Cytomegalovirus, and Toxoplasma gondii to microcephaly-related human proteins Inter-pathogen peptide sharing and the original antigenic sin: solving a paradox Anti-SARS-CoV-2 immune response and sudden death: titin as a link Experience with vaccination against influenza in the spring of 1947: a preliminary report Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences Peptide cross-reactivity: the original sin of vaccines The Author(s) Immunogenicity, immunopathogenicity, and immunotolerance in one graph From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry Immunobiology: on the inexistence of a negative selection process Hydrophobicity and the physico-chemical basis of immunotolerance The role of proteomics in defining autoimmunity The Author(s)